Riskpilot← Back to searchSign inGet full accessSwecomedPharma AB
ABBankruptOrg 5569832396Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20141 employees
Revenue 2017
SEK 0
EBITDA margin
—
-504% vs 2016
Equity ratio
-448.6%
Financial strength
Net profit 2017
SEK -3,4M
-624% vs 2016
| Revenue | SEK 0 | — |
| EBITDA | SEK -3,3M | -504% |
| Net profit | SEK -3,4M | -624% |
| Total assets | SEK 580K | -67% |
| Equity | SEK -2,6M | -438% |
| Employees | 1 | — |
Legal name
SwecomedPharma AB
Org number
5569832396
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 september 2014
Share capital
SEK 0
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2017-06-30
Financial year
January – December
Company purpose
Aktiebolaget ska bedriva handel med hälso- och sjukvårds- produkter, läkemedel, vacciner, sjukhusprodukter, sjukhus- inredningar, apotek och apoteksprodukter samt utbildningsprogram för hälso- och sjukvård jämte därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenue | — | 1 951 | 0 |
| Staff expenses | — | — | — |
| EBITDA | 100 | 825 | −3 333 |
| Depreciation & amort. | −1 | −0 | −0 |
| EBIT | 99 | 825 | −3 333 |
| Net financials | — | −2 | −38 |
| Profit before tax | 98 | 824 | −3 371 |
| Tax | −22 | −181 | −0 |
| Net profit | 76 | 643 | −3 371 |
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Total assets | 3 089 | 1 783 | 580 |
| Equity | 126 | 769 | −2 602 |
| Long-term debt | 2 940 | 0 | 0 |
| Short-term debt | 23 | 1 014 | 3 182 |
| Total debt | 2 963 | 1 014 | 3 182 |
EBITDA margin
-333300000.0%
This company
15.8%
Market median
-2109493771% vs market
20152017
Equity ratio
-448.6%
This company
38.2%
Market median
-1274% vs market
20152017
Return on equity
-337100000.0%
This company
18.4%
Market median
-1832065317% vs market
20152017
Net profit margin
-337100000.0%
This company
8.1%
Market median
-4161728495% vs market
20152017
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152017
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
20152017
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-09-01 – 2015-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JW | Audit | 2020 | — | — |
YI Auditor Substitute | Auditor Substitute | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SwecomedPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan William Harry Andersson | Audit | 0 companies |
| Ylva I M Svärdsén Nordström | Auditor Substitute | 0 companies |
| Björn Hilding Almén | Board of Directors | 0 companies |
| Gunnar Boström | Chairman | 0 companies |
| Karl Erik Hilding Björkholm | Deputy Board Member | 0 companies |